US equities |
MU $1,068.59 ▼-1.78% NVDA $236.13 ▼-0.56% PLTR $202.03 ▲+4.07% SNDK $1,647.74 ▼-2.64% META $721.48 ▲+0.02% AMD $637.10 ▼-1.36% INTC $110.06 ▼-2.70% TSLA $372.09 ▼-1.51%
FinancialContent

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

1.165 -0.005 (-0.43%)
Delayed Quote Updated: 10:18 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript ↗
CEO Rajavelu discusses $105 million financing and SP001 immunology strategy. 
Via The Motley Fool
Topics Earnings
News headline image
Spero Therapeutics Q2 Earnings Call Highlights ↗
Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for... 
Via MarketBeat
Topics Earnings
Spero Therapeutics Inc (NASDAQ:SPRO) Reports Q4 Earnings Beat and Positive Regulatory Step ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Spero Therapeutics ↗
 
Via Benzinga
News headline image
An Overview of Spero Therapeutics's Earnings ↗
 
Via Benzinga
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Spero Therapeutics Inc (NASDAQ:SPRO) Posts Q3 Revenue and EPS Beat ↗
Spero Therapeutics (SPRO) smashed Q3 2025 earnings, with revenue of $5.44M beating $0 estimates and a narrower EPS loss of -$0.13. 
Via Chartmill
News headline image
Insights Ahead: Spero Therapeutics's Quarterly Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
SPERO THERAPEUTICS INC (NASDAQ:SPRO) Reports Mixed Q2 2025 Results with Revenue Beat but Stock Decline ↗
SPERO Therapeutics (SPRO) reported Q2 2025 results with $14.19M revenue, beating estimates, but shares fell 6.8%. Phase 3 trial for tebipenem HBr halted early for efficacy. 
Via Chartmill
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Unusual volume stocks in Friday's session ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are making the most noise in today's session. ↗
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast ↗
Via Benzinga
News headline image
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? ↗
GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S. 
Via Benzinga
News headline image
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled ↗
The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >